Advanced MRI Measures of Repair in Alemtuzumab Treated Patients

Inclusion Criteria: * Signed, informed consent form * Age 18 to 50 years old (inclusive) * Diagnosis of MS per update of McDonald criteria, and cranial MRI scan demonstrating white matter lesions attributable to MS within 10 years of screening * Onset of MS symptoms within 15 years of screening * Neurostatus (EDSS) score 0.0 to 5.0 (inclusive) * 2 MS attacks (first episode or relapse) occurring in the 24 months prior to screening, with 1 attack in the 12 months prior to screening, with objective neurological signs confirmed by a physician. Exclusion Criteria: * Received prior therapy for MS other than corticosteroids within 28 days of screening; e.g., interferon's, IV immunoglobulin, and glatiramer acetate * Exposure to natalizumab within 6 months of screening * Any prior exposure to mitoxantrone, mycophenolate mofetil, azathioprine, cladribine, cyclophosphamide, cyclosporine A, methotrexate, rituximab, or any other immunosuppressive agent other than systemic corticosteroid treatment * Has any progressive form of MS * History of malignancy (exception for basal cell skin carcinoma) * Previous hypersensitivity reaction to other immunoglobulin product * Intolerance of pulsed corticosteroids, especially a history of steroid psychosis * CD4+, CD8+, or CD19+ (i.e., absolute CD3+CD4+, CD3+CD8+, or CD19+/mm3) count \<LLN at Screening; if abnormal cell count(s) return to within normal limits, eligibility may be reassessed * Seropositivity for human immunodeficiency virus (HIV) * Si…